register

Leadership & Management

Leadership transition at Chiesi Australia as Micevski succeeds McGregor as GM

Health Industry Hub | July 8, 2026 |

Chiesi Australia’s General Manager, Melissa McGregor, will leave the company at the end of July to focus on the health and wellbeing of herself and her family, and to permanently return to Brisbane. Senior Director of Business Unit AIR and Care Billy Micevski will succeed McGregor as General Manager, taking the helm following her departure.

The company said McGregor made a significant contribution to the growth of the Australian affiliate and its culture.

“It has been a privilege to lead Chiesi Australia and work alongside such a passionate and purpose- driven team. I am immensely proud of what we have achieved together and grateful for the support and collaboration of so many colleagues,” said McGregor, reflecting on her time leading Chiesi Australia. “I am also delighted to congratulate Billy Micevski on his appointment as General Manager. Having worked closely with him over the years, I have every confidence in his leadership and in the organisation’s future. I look forward to seeing Chiesi Australia continue to thrive under his leadership and the impact it will continue to have for Australian patients.”

Raised in the regional town of Mildura, McGregor pivoted from her family’s agricultural roots to build a distinguished career spanning over three decades in the healthcare sector. She is widely recognised for her 20-year tenure at Pfizer, where she rose through the ranks to become the Managing Director for the ANZ affiliate before taking on a prominent European VP leadership role. In 2024, she returned to Australia to head Chiesi’s operations and has been a powerful voice for the pharma industry, serving as a member of the Board of Directors for Medicines Australia.

“I’d like to thank Melissa for her leadership and contribution, and wish her every success in her future endeavours. As I step into the role of General Manager, I’m excited to build on the strong foundations,” commented Micevski, one of the founding members who helped establish Chiesi Australia’s affiliate in 2019. “With our people at the heart of everything we do, I look forward to working alongside our teams and partners to deliver meaningful impact for Australian patients, their families and caregivers, while continuing to strengthen our commitment to innovation, collaboration and sustainability.”

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


News - Pharmaceuticals

Inside the tensions shaping PBAC decision

Inside the tensions shaping PBAC decision

Health Industry Hub | September 17, 2026 |

The evolving relationship between sponsors, the Pharmaceutical Benefits Advisory Committee (PBAC) and the health technology assessment (HTA) system came under […]

More


News - MedTech & Diagnostics

GenesisCare and Omico join forces in precision oncology as Australia sets national genomics agenda

GenesisCare and Omico join forces in precision oncology as Australia sets national genomics agenda

Health Industry Hub | September 17, 2026 |

GenesisCare and Omico are teaming up to bring precision oncology to more patients facing incurable, advanced or poor prognosis cancers. […]

More


News - MedTech & Diagnostics

MTAA Board election kicks off, setting stage for the next chapter in policy and advocacy

MTAA Board election kicks off, setting stage for the next chapter in policy and advocacy

Health Industry Hub | September 17, 2026 |

The race for six seats on the Medical Technology Association of Australia (MTAA) Board is underway, with 10 candidates nominated […]

More


News - Pharmaceuticals

New breast cancer drug fills gap left by Zoladex market withdrawal

New breast cancer drug fills gap left by Zoladex market withdrawal

Health Industry Hub | September 17, 2026 |

From 1 October 2026, Diphereline (triptorelin 3.75mg) will become available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of […]

More


This content is copyright protected. Please subscribe to gain access.